231 related articles for article (PubMed ID: 28413663)
1. Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.
Richardson K; Alrifai T; Grant-Szymanski K; Kouris GJ; Venugopal P; Mahon B; Karmali R
Mol Clin Oncol; 2017 Apr; 6(4):539-542. PubMed ID: 28413663
[TBL] [Abstract][Full Text] [Related]
2. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
3. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.
Johnson L; O'Donoghue JM; McLean N; Turton P; Khan AA; Turner SD; Lennard A; Collis N; Butterworth M; Gui G; Bristol J; Hurren J; Smith S; Grover K; Spyrou G; Krupa K; Azmy IA; Young IE; Staiano JJ; Khalil H; MacNeill FA
Eur J Surg Oncol; 2017 Aug; 43(8):1393-1401. PubMed ID: 28596034
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.
Patzelt M; Zarubova L; Klener P; Barta J; Benkova K; Brandejsova A; Trneny M; Gürlich R; Sukop A
Aesthetic Plast Surg; 2018 Apr; 42(2):451-455. PubMed ID: 29101436
[TBL] [Abstract][Full Text] [Related]
5. Stage IV Breast Implant-associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy.
Thibodeau R; Fan KL; Wehner PB
Plast Reconstr Surg Glob Open; 2019 Sep; 7(9):e2446. PubMed ID: 31942403
[TBL] [Abstract][Full Text] [Related]
6. Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin.
Stack A; Ali N; Khan N
J Cell Immunol; 2020 May; 2(3):80-89. PubMed ID: 32914146
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
9. Update on the Treatment of Anaplastic Large Cell Lymphoma.
Vu K; Ai W
Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
[TBL] [Abstract][Full Text] [Related]
10. Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Rastogi P; Deva AK; Prince HM
Curr Hematol Malig Rep; 2018 Dec; 13(6):516-524. PubMed ID: 30345474
[TBL] [Abstract][Full Text] [Related]
11. Breast implant-associated anaplastic large cell lymphoma in an Asian patient: The first case report from Thailand.
Thienpaitoon P; Disphanurat W; Warnnissorn N
Arch Plast Surg; 2020 Sep; 47(5):478-482. PubMed ID: 32713177
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
13. Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?
Fitzal F; Turner SD; Kenner L
Open Biol; 2019 Apr; 9(4):190006. PubMed ID: 30939983
[TBL] [Abstract][Full Text] [Related]
14. Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis.
Vittorietti M; Mazzola S; Costantino C; De Bella DD; Fruscione S; Bonaccorso N; Sciortino M; Costanza D; Belluzzo M; Savatteri A; Tramuto F; Contiero P; Tagliabue G; Immordino P; Vitale F; Di Napoli A; Mazzucco W
Front Oncol; 2023; 13():1202733. PubMed ID: 37927474
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma.
Stack A; Levy I
Clin Case Rep; 2019 May; 7(5):1003-1006. PubMed ID: 31110735
[TBL] [Abstract][Full Text] [Related]
17. Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).
Lee JH
Yeungnam Univ J Med; 2021 Jul; 38(3):175-182. PubMed ID: 33461261
[TBL] [Abstract][Full Text] [Related]
18. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.
St Cyr TL; Pockaj BA; Northfelt DW; Craig FE; Clemens MW; Mahabir RC
Plast Surg (Oakv); 2020 May; 28(2):117-126. PubMed ID: 32596187
[TBL] [Abstract][Full Text] [Related]
19. An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Premji S; Barbieri A; Roth C; Rohren EM; Rivero G; Teegavarapu SP
Case Rep Hematol; 2022; 2022():4700787. PubMed ID: 35721802
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
